These data, in conjunction with the notion that a certain proportion of human cancers contains disruption of the Rb-pathway, strongly suggest that treatment with CDK inhibition may promote tumour development, depending on the level of expression of CX3CL1 and the Rb status in the tumour. This evidence concerns the gene CX3CL1 and neoplasm.